Epilepsy

Rodney Allan Radtke, MD, professor of neurology at Duke University School of Medicine in Durham, North Carolina, discussed some of the new therapeutic options available to help improve tolerance and adherence challenges that clinicians commonly face in epilepsy practice.

The professor of neurology at the Icahn School of Medicine at Mount Sinai discussed what still needs to be done to clarify medical marijuana’s position in medicine.

A 23-year-old male college student presents with first generalized tonic-clonic seizure followed by episodes of violent psychosis.

The associate chief of the MS division and professor of neurology at the University of Pennsylvania described the relationship between artificial intelligence and medicine, and how he sees it evolving in the future.

Neurology News Network for the week ending August 17, 2019.

A generally healthy, young adult male presents with first generalized tonic-clonic seizure followed by episodes of violent psychosis.

The pediatric neurologist and epilepsy specialist at Children’s Hospital Colorado spoke about patient interest in cannabidiol after the FDA approval of Epidiolex, and what remains to be done to perfect its use in epilepsy.

The product includes cannabidiol that is encased in a gelatin bead inside a gastro-resistant capsule to help promote optimal absorption and reduce adverse events associated with other oral CBD formulations.

The new drug application for Libervant is expected to be completed in the fourth quarter of 2019, which if approved, would offer a potentially first in class oral treatment for breakthrough or cluster seizures.

Neurology News Network for the week ending August 10, 2019.

Exposure to the care of either a neurologist or comprehensive epilepsy program epileptologist resulted in a significantly lower rate of premature mortality than that of those who were not, based on findings from a cohort of more than 20,000 cases.

The associate professor of neurology and medical director of the epilepsy monitoring unit and Penn epilepsy surgical program at the University of Pennsylvania discussed the findings of a single-center review of off-label clobazam use for patients with drug-refractory epilepsy.

The new drug application for Libervant is expected to be completed in the fourth quarter of 2019, which if approved, would offer a potentially first in class oral treatment for breakthrough or cluster seizures.

The associate professor of neurology and medical director of the epilepsy monitoring unit and Penn epilepsy surgical program at the University of Pennsylvania shared insight into the prioritization of women with epilepsy who may intend to get pregnant.

The clinical neuropsychologist and head of the School of Psychological Sciences at the University of Melbourne discussed the results of a study she and colleagues conducted in which they mapped the long-term social outcomes of patient post-epilepsy surgery.

The clinical neuropsychologist and head of the School of Psychological Sciences at the University of Melbourne detailed how the transition from states of illness to wellness after epilepsy surgery can result not just in brain changes, but psychosocial challenges for patients.

Mind Moments® a podcast from NeurologyLive®, brings you exclusive interviews with experts in neurologic disorders.

The staff neurologist at Cleveland Clinic’s Mellen Center for MS shared her insight into the use of telemedicine in an outpatient setting across a number of subspecialties in neurology and how it can supplement care going forward.

The clinical neuropsychologist and head of the School of Psychological Sciences at the University of Melbourne spoke about what physicians need to provide to help patients through the adjustment period after epilepsy surgery.

The FDA has assigned the application a PDUFA target action date of March 17, 2020.

The clinical neuropsychologist and head of the School of Psychological Sciences at the University of Melbourne discussed the early-stage research into neurorehabilitation post-epilepsy surgery, and the promise it might hold to address surgery’s long-term risks.

On our anniversary, take a look back at some of our most popular articles and interviews across a range of neurology topics.

The director of the Jefferson Comprehensive Epilepsy Center discussed what’s currently being developed in the treatment of epilepsy, as well as the emergence of different methods of stimulation and neuromodulation.

Zogenix has announced that its Study 1601 of fenfluramine (Fintepla), also known as ZX008, in the treatment of seizures associated with Lennox-Gastaut syndrome has completed enrollment and is on schedule to report top-line data in Q1 2020.

The University of Alabama at Birmingham neuromodulation epilepsy clinic has treated 43 patients with drug-resistant epilepsy, reducing seizures by >60% for a number of patients with both vagus nerve stimulation and responsive neurostimulation techniques.

At least 30% of patients with epilepsy have seizures that are incompletely controlled by medical therapy; thus, nonpharmacological options are important for comprehensive care.

The professor and chief of pediatric neurology at Le Bonheur Children’s Hospital and the University of Tennessee Health Science Center discussed the decision-making process for choosing interventions for patients with epilepsy, and how to keep patients adherent.

Pregabalin is approved for use in partial onset seizures, as well as postherpetic neuralgia, fibromyalgia, and for the management of neuropathic pain associated with spinal cord injury and diabetic peripheral neuropathy.

The professor and chief of pediatric neurology at Le Bonheur Children’s Hospital and the University of Tennessee Health Science Center spoke about the concerns of uncontrolled epilepsy and how to determine if a patient requires more than one treatment for their epilepsy.

The pediatric neurologist and epilepsy specialist at Children’s Hospital Colorado discussed the popularity of cannabidiol from coverage in the media, and how she sees its use—and the understanding of it—evolving in the coming years.